（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：8513） （ 前稱 IAG Holdings Limited 官醞控股有限公司 ） 董事名單及其角色和職能 加和國際控股有限公司董事（「董事」）會（「董事會」）成員載列如下： 執行董事 MaxWin International Holdings Limited 加和國際控股有限公司 潘瑞河先生 （主席） 徐斌女士 李仁剛先生 楊淇鈞先生 獨立非執行董事 張嘉裕教授 傅思安先生 陳藝華女士 董事會已成立三個委員會，而各委員會的成員載列如下： 審核委員會 張嘉裕教授 （主席） 傅思安先生 陳藝華女士 提名委員會 潘瑞河先生 （主席） 張嘉裕教授 傅思安先生 陳藝華女士 薪酬委員會 傅思安先生 （主席） 潘瑞河先生 張嘉裕教授 二零二五年八月十五日 ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：8513） 委任獨立非執行董事、 審核委員會及提名委員會成員 加和國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」）會（「董 事會」）欣然宣佈，陳藝華女士（「陳女士」）已獲委任為獨立非執行董事、本公司審核委員 會成員及本公司提名委員會成員，自二零二五年八月十五日起生效。 陳女士擁有豐富的財務經驗。陳女士於一九八四年至一九九四年擔任中國人民保險公司 內部審計部助理會計師，於一九九四年至二零零五年任職於深圳市深財證券業務部財務部， 並於二零零五年至二零一二年擔任萬和證券股份有限公司財務經理。陳女士於二零一二 年退任。 陳女士於一九七九年畢業於廣西財經學院，為項目預算及經濟學專家。 陳女士與本公司訂立委任函，自二零二五年八月十五日起計為期三年。陳女士須根據本 公司組織章程細則於股東週年大會上退任及膺選連任。陳女士享有年度董事袍金170,000 港元。 於本公告日期，除上文所披露者外，陳女士已確認： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 承董事會命 加和國際控股有限公司 主席 潘瑞河 新加坡，二零二五年八月十四日 於本公告日期，本公司執行董事為潘瑞河先生、李仁剛先生、徐斌女士及楊淇鈞先生；以及本公司獨立非 執行董事為張嘉裕博士及傅思安先生。 本公告的資料乃遵照《香港聯合交易所有限公司的 GEM 證券上市規則》而刊載，旨在提供有關本公司的資 料；本公司的董事願就本公告的資料共同及個別地承擔全部責任。本公司各董事在作出一切合理查詢後， 確認就其所知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任 何事項，足以令致本公告或其所載任何陳述產生誤導。 本公告將由刊登日期起計最少七天於聯交所網站 www.hkexnews.hk「最新上市公司公告」網頁刊登。本公 告亦將於本公司網站 www.inzign.com 刊登。 MaxWin International Holdings Limited 加和國際控股有限公司 (於 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加和國際控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08513 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [2] - Established in 1981, the company has become a reliable contract manufacturer for major international healthcare and medical device companies [2] - The company's revenue is derived from two main segments: manufacturing and selling disposable medical device components, and providing mold-making services [2] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, showing a year-on-year increase of 61% [1] - The gross profit margin stood at 2.18%, while the debt-to-asset ratio was 75.71% [1] Market Position and Valuation - 加和国际控股's price-to-earnings (P/E) ratio is -6.88, ranking 85th in the industry, compared to the average P/E ratio of -2.68 for the healthcare equipment and services sector [1] - The company has experienced a cumulative decline of 11.19% over the past month and a 28.25% decline year-to-date, underperforming the Hang Seng Index, which has risen by 19.78% [1] - Currently, there are no investment rating recommendations from institutions for 加和国际控股 [1] Industry Context - The healthcare equipment and services industry has an average P/E ratio of -2.68, with a median of 1.17 [1] - Other companies in the industry include 巨星医疗控股 (02393.HK) with a P/E of 0.28, 京玖康疗 (00648.HK) at 0.38, 医汇集团 (08161.HK) at 1.96, 环球医疗 (02666.HK) at 5.24, and 瑞慈医疗 (01526.HK) at 5.4 [1]

Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [3] - The company was established in 1981 and has become a reliable contract manufacturer for major international healthcare and medical device companies [3] - The revenue streams of the company include manufacturing and selling disposable medical device components and providing mold-making services [3] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [2] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, which is a year-on-year increase of 61% [2] - The gross profit margin stands at 2.18%, while the debt-to-asset ratio is 75.71% [2] Market Position and Valuation - Over the past month, 加和国际控股 has experienced a cumulative decline of 10.34%, and a year-to-date decline of 26.55%, underperforming the Hang Seng Index, which has increased by 18.2% [2] - The company's price-to-earnings (P/E) ratio is -7.04, ranking 83rd in the industry, while the average P/E ratio for the healthcare equipment and services industry is -21.64 [2] - Other companies in the same sector have P/E ratios such as 巨星医疗控股 at 0.33, 京玖康疗 at 0.38, 永胜医疗 at 4.25, 环球医疗 at 4.64, and 瑞慈医疗 at 5.2 [2]

Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [2] - Established in 1981, the company has become a reliable contract manufacturer for major international healthcare and medical device companies [2] - The company's revenue is derived from two main segments: manufacturing and selling injection-molded plastic components for disposable medical devices, and providing mold-making services [2] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, which is a 61% increase compared to the previous period [1] - The gross profit margin stands at 2.18%, with a debt-to-asset ratio of 75.71% [1] Market Position and Valuation - 加和国际控股's price-to-earnings (P/E) ratio is -6.71, ranking 83rd in its industry, while the average P/E ratio for the healthcare equipment and services sector is -21.39 [1] - The company has underperformed the Hang Seng Index, with a cumulative decline of 29.94% year-to-date, compared to the index's increase of 20.55% [1] - Currently, there are no investment rating recommendations from institutions for 加和国际控股 [1] Industry Context - The healthcare equipment and services industry has an average P/E ratio of -21.39, with a median of 0.3 [1] - Competitors in the industry include other companies with varying P/E ratios, such as 巨星医疗控股 at 0.22, 京玖康疗 at 0.38, and 永胜医疗 at 3.83 [1]

Company Overview - 加和国际控股有限公司 is a contract manufacturer headquartered in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [3] - The company was established in 1981 and has become a reliable contract manufacturer for major international healthcare and medical device companies [3] - The revenue streams of the company include manufacturing and selling injection-molded plastic components for disposable medical devices and providing mold-making services [3] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, which is a 61% increase compared to the previous year [1] - The gross profit margin stands at 2.18%, while the debt-to-asset ratio is 75.71% [1] Market Position and Valuation - Currently, there are no institutional investment ratings for 加和国际控股 [2] - The company's price-to-earnings (P/E) ratio is -7.04, ranking 82nd in the industry, while the average P/E ratio for the healthcare equipment and services industry is -20.22 [2] - Other companies in the industry have varying P/E ratios, with 巨星医疗控股 at 0.22, 京玖康疗 at 0.38, 永胜医疗 at 3.78, 环球医疗 at 4.64, and 瑞慈医疗 at 5.45 [2]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of approximately SGD 10.5 million, an increase from SGD 9.1 million in the previous fiscal year[11]. - The gross profit turned positive at SGD 0.2 million, compared to a gross loss of SGD 0.7 million in the fiscal year 2023, indicating improved cost management[11]. - The net loss for the fiscal year 2024 was approximately SGD 2.6 million, significantly reduced from a net loss of SGD 6.8 million in the fiscal year 2023[11]. - The group's revenue increased by approximately SGD 1.4 million or 15.4% from SGD 9.1 million in FY2023 to approximately SGD 10.5 million in FY2024, primarily due to sales and manufacturing of disposable medical device injection molded plastic components in Singapore[19]. - The overall gross profit improved from a gross loss of approximately SGD 0.7 million in FY2023 to a gross profit of approximately SGD 0.2 million in FY2024, representing an increase of approximately SGD 0.9 million or 128.6%[21]. - The net other income increased from a net loss of approximately SGD 15,000 in FY2023 to a net other income of approximately SGD 0.2 million in FY2024, attributed to gains from lease termination and foreign exchange gains[23]. - Total comprehensive loss for the year was SGD 2,631,000, down from SGD 6,835,000 in 2023, showing a 61% improvement[173]. - The company reported a net loss from continuing operations of SGD 2,631,000 for 2024, compared to SGD 4,685,000 in 2023[173]. - Other income increased significantly to SGD 759,000 in 2024 from SGD 90,000 in 2023, marking a growth of 743%[173]. Operational Changes - The company successfully sold its gaming machines and equipment division in December 2023, allowing it to focus on core business areas[13]. - The company has ceased its gaming machine and equipment operations, focusing on manufacturing and selling disposable medical devices[185]. - The company continues to explore new revenue sources and business opportunities to mitigate external economic challenges[17]. - The company is committed to operational optimization and enhancing efficiency across its business units[13]. - Strategic resource allocation and strict cost control measures have been implemented to align business strategies with changing market conditions[12]. Governance and Management - The company has appointed new executive directors, including Mr. Li and Mr. Yang, effective from October 1, 2024, and November 22, 2024, respectively[49][50]. - The company’s founder, Mr. Pan, has been with the group since 1981 and plays a crucial role in overall management and business development[45]. - The board of directors includes experienced professionals with extensive backgrounds in finance, management, and consulting[51][53]. - The company emphasizes the importance of sound corporate governance for long-term success and sustainable development, maintaining high standards and procedures to enhance accountability and transparency[63]. - The company has complied with the corporate governance code, except for the provision that the roles of chairman and CEO should be separated, which is currently held by Mr. Pan[64]. - The board consists of seven members, including four executive directors and three independent non-executive directors, ensuring independent judgment[68]. - The company has established three functional committees to assist the board in fulfilling its responsibilities, including the audit committee, remuneration committee, and nomination committee[77]. - The company has adopted trading standards for directors' securities transactions, confirming compliance during the fiscal year 2024[75]. Financial Position and Cash Flow - The current ratio improved to approximately 1.8 times as of December 31, 2024, compared to 1.4 times in 2023, due to increases in trade and other receivables[29]. - The total borrowings decreased to approximately SGD 2.4 million as of December 31, 2024, down from SGD 4.2 million in 2023[30]. - The company reported a decrease in cash used in investing activities, with cash outflow for the purchase of property, plant, and equipment increasing to SGD 255,000 from SGD 47,000[183]. - The total cash and cash equivalents at the end of 2024 rose to SGD 1,779,000, up from SGD 1,598,000 at the end of 2023, indicating a positive cash flow trend[183]. - The company received a loan from a shareholder amounting to SGD 2,000,000, which was not present in the previous year[183]. - The company’s cash flow from operating activities was not detailed in the provided documents, indicating a need for further analysis in future reports[183]. Compliance and Risk Management - The company is committed to complying with insider information disclosure regulations and has engaged a third-party firm to review internal controls[98]. - The company confirmed that the consolidated financial statements for the fiscal year 2024 were prepared in accordance with relevant accounting standards and principles, reflecting the group's true and fair condition, performance, and cash flows[99]. - The audit committee discussed internal controls and financial reporting matters for the fiscal year 2024, confirming compliance with applicable standards and regulations[82]. - The independent auditor has confirmed that the consolidated financial statements reflect the group's financial position as of December 31, 2024, in accordance with International Financial Reporting Standards[157]. - The company has complied with applicable laws and regulations, ensuring that its operations meet significant legal requirements[119]. Shareholder Engagement - The board of directors is committed to maintaining effective and ongoing communication with shareholders and potential investors[101]. - The company encourages all shareholders to attend the annual general meeting and future meetings to maintain good communication[106]. - The company has received annual independence confirmations from all independent non-executive directors as required by GEM listing rules[129]. Future Outlook - Future outlook remains cautious with ongoing assessments of cash flow forecasts and key assumptions impacting financial performance[173]. - The company is actively exploring future development opportunities and market expansion strategies[41].

Dividend Information - The company does not recommend the payment of a final dividend for the fiscal year ending December 31, 2024[4] Performance Announcement - The annual performance announcement is scheduled for March 27, 2025, covering the fiscal year ending December 31, 2024[3] Information Accuracy and Transparency - The board of directors confirms the accuracy and completeness of the information provided in the announcement[4] - The company has a commitment to transparency and accountability regarding the information disclosed[4] - The company emphasizes that there are no misleading or fraudulent elements in the announcement[4] Regulatory Compliance - The announcement aims to provide information about the company in accordance with the GEM listing rules[4] Publication Details - The announcement will be published on the Hong Kong Stock Exchange website for at least seven days from the publication date[4] - The announcement will also be available on the company's official website[4] Company Information - The company is registered in the Cayman Islands and operates under the stock code 8513[2] - The board consists of both executive and independent non-executive directors[4]